Commonwealth Equity Services
IMUX icon

Commonwealth Equity Services’s Immunic IMUX Stock Holding History

Commonwealth Equity Services’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,036
Closed -$11.5K – 4496
2026
Q1 		$11.5K Buy
+1,036
New +$9.28K ﹤0.01% 4276

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Commonwealth Equity Services's IMUX Position: Q2 2026 in Review

Commonwealth Equity Services sold out of Immunic (IMUX) in Q2 2026, closing a stake of 1,036 shares — an estimated $11.5K sold.

Commonwealth Equity Services first reported a position in IMUX in Q1 2026 and held it in 1 quarter. The position peaked at $11.5K in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Commonwealth Equity Services reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
  • Commonwealth Equity Services sold 1,036 Immunic shares in Q2 2026, an estimated $11.5K.
  • Commonwealth Equity Services first reported a position in Immunic in Q1 2026 and held it in 1 quarter.
  • Commonwealth Equity Services's Immunic position peaked at $11.5K in Q1 2026.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Commonwealth Equity Services's 13F filing for Q2 2026, filed 29 Jul 2026.